Next Article in Journal
Erratum: Michael A. Picker; et al.; H-NS, Its Family Members and Their Regulation of Virulence Genes in Shigella Species. Genes 2016, 7, 112
Previous Article in Journal
Haplotypes of the Ovine Adiponectin Gene and Their Association with Growth and Carcass Traits in New Zealand Romney Lambs
Previous Article in Special Issue
Dystrophic Cardiomyopathy—Potential Role of Calcium in Pathogenesis, Treatment and Novel Therapies
Article Menu
Issue 6 (June) cover image

Export Article

Open AccessReview
Genes 2017, 8(6), 161; doi:10.3390/genes8060161

Splice-Switching Therapy for Spinal Muscular Atrophy

Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford OX1 3QX, UK
*
Author to whom correspondence should be addressed.
Academic Editors: Susan Fletcher and Steve Wilton
Received: 21 April 2017 / Revised: 26 May 2017 / Accepted: 2 June 2017 / Published: 12 June 2017
(This article belongs to the Special Issue Therapeutic Alternative Splicing: Mechanisms and Applications)
View Full-Text   |   Download PDF [418 KB, uploaded 12 June 2017]   |  

Abstract

Spinal muscular atrophy (SMA) is a genetic disorder with severity ranging from premature death in infants to restricted motor function in adult life. Despite the genetic cause of this disease being known for over twenty years, only recently has a therapy been approved to treat the most severe form of this disease. Here we discuss the genetic basis of SMA and the subsequent studies that led to the utilization of splice switching oligonucleotides to enhance production of SMN protein, which is absent in patients, through a mechanism of exon inclusion into the mature mRNA. Whilst approval of oligonucleotide-based therapies for SMA should be celebrated, we also discuss some of the limitations of this approach and alternate genetic strategies that are currently underway in clinical trials. View Full-Text
Keywords: spinal muscular atrophy; splice-switching oligonucleotides; clinical trials spinal muscular atrophy; splice-switching oligonucleotides; clinical trials
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Meijboom, K.E.; Wood, M.J.; McClorey, G. Splice-Switching Therapy for Spinal Muscular Atrophy. Genes 2017, 8, 161.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Genes EISSN 2073-4425 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top